Full-Time

Director/Senior Director

Clinical Science

Posted on 3/24/2024

Coherus BioSciences

Coherus BioSciences

201-500 employees

Develops and commercializes biosimilars for healthcare

Compensation Overview

$190k - $260k/yr

Senior, Expert

San Carlos, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • PhD degree in health science field, PharmD, MD or non-US equivalent, or other relevant advanced degree in a health science field
  • Minimum 7+ years of experience for Director, 12+ years of experience for Senior Director at a pharmaceutical, CRO or biotechnology company as a clinical scientist or related role
  • Early stage drug development experience required
  • Experience with data analysis and interpretation
  • Thorough understanding of the drug development process
  • Broad understanding of functional areas of drug development, including preclinical, regulatory, pharmacovigilance, drug supply, data sciences (data management, biostatistics, programming), and clinical operations (including site selection, study start-up, study conduct, and finalization)
  • Demonstrated ability to communicate and write clearly, concisely, and effectively
  • Ability to understand, interpret and communicate clinical information including literature reviews, competitive intelligence, and changing treatment paradigms in order to apply knowledge to support a robust clinical development strategy
  • Understanding of trial design and statistics
  • Ability to interpret, analyze, and present clinical data
  • Well-organized: ability to prioritize tasks with a successful track record of managing multiple projects in a fast-paced and deadline-driven environment
  • Impeccable attention to detail
Responsibilities
  • Partner with cross-functional program team members and key R&D stakeholders to contribute to the clinical strategy and creation of clinical development plans for one or more candidate clinical drug products
  • Provide clinical support for clinical study conduct, including operational feasibility, data management, communication plans, safety and medical monitoring, preparation of meeting materials and study updates
  • Perform medical and safety/efficacy data reviews. Prepare and communicate clear overviews of trial results
  • Identify issues related to study conduct and/or subject safety. Provide preliminary assessments and recommendations and collaborate with the clinical team to develop solutions ensure resolution
  • Provide organizational support for data review committees including operationalizing the charter, preparing updates and data reviews, development of meeting materials and data reports and execution of meetings
  • Author protocols and contribute to authoring of clinical study reports, IBs, ICFs, training documents, and other clinical and regulatory documents
  • Interact with internal and external stakeholders (study sites, vendors, KOLs, etc.) in support of program-level strategy as well as clinical trial objectives
  • Act as recognized clinical expert for assigned programs
  • Lead development of abstracts, posters, and content for scientific meetings, conferences and publications
Desired Qualifications
  • Experience in oncology or oncology immunotherapy clinical trials preferred

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. The company focuses on improving patient lives by expanding access to these essential treatments, helping to offset rising healthcare costs. Coherus operates in the biopharmaceutical market, serving healthcare providers, hospitals, and patients, and follows a rigorous approval process to ensure product quality and efficacy. By providing cost-effective alternatives to original biologics, Coherus aims to enhance healthcare accessibility while maintaining a competitive edge in the market.

Company Size

201-500

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on immuno-oncology enhances pipeline and market position.
  • Launch of Udenyca wearable injector device improves drug delivery systems.
  • Strategic collaborations could lead to new partnerships and investment opportunities.

What critics are saying

  • Exit from biosimilar space may lead to loss of market share.
  • 30% staff reduction could affect innovation and productivity.
  • Collaboration with Cancer Research Institute may face scientific and regulatory hurdles.

What makes Coherus BioSciences unique

  • Focus on biologic therapeutics for oncology and inflammatory diseases.
  • Expertise in process science and analytical characterization.
  • Commitment to high-quality, cost-effective biosimilars.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

4%

2 year growth

4%
PharmiWeb
May 28th, 2025
Storm Therapeutics Announces First Patient Dosed In Clinical Collaboration To Evaluate Stc-15 In Combination With Loqtorzi® And Appointment Of Atif Abbas, M.D., As Chief Medical Officer

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer. STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor

Fierce Pharma
Apr 23rd, 2025
Coherus loses commercial chief amid exit from biosimilar space

Coherus hired Sameer Goregaoker as senior VP of immuno-oncology marketing and Loqtorzi brand lead late last year.

ETF Daily News
Mar 29th, 2025
Intech Investment Management LLC Makes New $38,000 Investment in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Intech Investment Management LLC makes new $38,000 investment in Coherus BioSciences, Inc. (NASDAQ:CHRS).

Stock Titan
Feb 24th, 2025
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Coherus BioSciences (NASDAQ: CHRS) has announced its senior management's upcoming participation in the 45th Annual TD Cowen Health Care Conference.

PE Hub
Jul 3rd, 2024
SK Capital's Apotex to acquire Canadian rights to Toripalimab

SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences.

INACTIVE